Transplant-Ineligible Myeloma: Can Daratumumab + Bortezomib Maintenance Improve Outcomes? | #IMS26

Transplant-Ineligible Myeloma: Can Daratumumab + Bortezomib Maintenance Improve Outcomes? | #IMS26
Does Intensive Treatment Affect Quality of Life in High-Risk Myeloma? | RADAR Trial | IMS 2026
Belantamab Mafodotin in Myeloma: Can a Questionnaire Replace Eye Exams? | IMS 2026
Colon cancer in young adults: symptoms, risk factors and screening

What a 3-Month PET-CT Can Predict About CAR-T Outcomes in Multiple Myeloma | IMS 2026
Can Multiple Myeloma Be Cured? MRD Negativity, Stopping Treatment & Confirming Cure | IMS 2026
AL Amyloidosis Bispecific Trial: Who Qualifies, Response , Side Effects & Organ Response | IMS 2026
Multiple Myeloma Treatment for Older Adults: Who Should Get Quadruplet Therapy? | IMS 2026
In Vivo CAR-T for Multiple Myeloma: Could It Improve Access and Skip Chemotherapy? | IMS 2026